UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000033420
Receipt number R000038106
Scientific Title Detection and kinetics of IL-38 positive cells in induced sputum in atopic mild adult asthmatics after allergen challenge
Date of disclosure of the study information 2018/08/01
Last modified on 2024/01/21 08:02:57

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Detection and kinetics of IL-38 positive cells in induced sputum in atopic mild adult asthmatics after allergen challenge

Acronym

IL-38 positive cells in atopic asthma

Scientific Title

Detection and kinetics of IL-38 positive cells in induced sputum in atopic mild adult asthmatics after allergen challenge

Scientific Title:Acronym

IL-38 positive cells in atopic asthma

Region

Japan


Condition

Condition

Atopic mild adult asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Detection of IL-38 positive cells in induced sputum and peripheral blood in patients with asthma and healthy subjects.

Basic objectives2

Others

Basic objectives -Others

Kinetics of IL-38 positive cells in induced sputum and peripheral blood in patients with asthma pre and after allergen challenge

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Primary endpoint is to investigate the correlation frequency of IL-38 positive cells per macrophage or monocytes in induced sputum and airway inflammation, hyperresponsiveness on methacholine, and asthmatic response after allergen challenge in atopic mild adult asthmatics.

Key secondary outcomes

Secondary endpoint is investigate the correlation frequency of IL-38 positive cells per macrophage or monocytes in induced sputum and peripheral blood in atopic mild adult asthmatics. We investigate whether frequency of IL-38 positive cells per macrophage or monocytes induced sputum and peripheral blood will be able to usefulness to evaluate the pathogenesis and severity of asthma as a biomarker.


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. mild asthmatics and healthy non-smoking controls
2. Non-smokers
3. Stable for at least 4wks
4. %forced vital capacity >80% predicted, %forced expiratory volume in 1 sec, >80% predicted and a ratio FEV1/FVC >0.7

Key exclusion criteria

1. Difficulty expectoration of induced sputum
2. Presence of any other moderate and severe comorbidities
3. Current or ex-smokers
4. participants who have judged that research directors and researchers are inappropriate as research subjects
5. Nursing and pregnancy

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Tomotaka
Middle name
Last name Kawayama

Organization

Kurume University

Division name

Department of medicine

Zip code

830-0011

Address

67 Asahimachi, Kurume

TEL

0942-31-7560

Email

kawayama_tomotaka@med.kurume-u.ac.jp


Public contact

Name of contact person

1st name Tomotaka
Middle name
Last name Kawayama

Organization

Kurume University

Division name

Department of medicine

Zip code

830-0011

Address

67 Asahimachi, Kurume

TEL

0942-31-7560

Homepage URL


Email

kawayama_tomotaka@med.kurume-u.ac.jp


Sponsor or person

Institute

Department of medicine, Kurume University

Institute

Department

Personal name



Funding Source

Organization

Department of medicine, Kurume University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kurume University

Address

67 Asahimachi, Kurume

Tel

0942-35-3311

Email

sangakuml@kurume-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 08 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2018 Year 07 Month 31 Day

Date of IRB

2018 Year 07 Month 18 Day

Anticipated trial start date

2018 Year 08 Month 01 Day

Last follow-up date

2024 Year 12 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Cross-sectional study


Management information

Registered date

2018 Year 07 Month 17 Day

Last modified on

2024 Year 01 Month 21 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038106


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name